Iben Lyskjær, PhD, is an associate professor and leader of the Lyskjær Group at the Department of Molecular Medicine (MOMA) at Aarhus University.

Ablation, a minimally invasive procedure, may be as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications, according to new research.

The findings come from a 10-year nationwide registry-based cohort study of Danish adults following 1900 patients diagnosed with stage T1a renal cell carcinoma and suggest ablation could potentially reduce complications, hospital stays, and costs.

The study included 1,862 patients, with a median age of 64, and a majority of men (n = 1305). They were categorized into the ablation group (n = 540), the resection group (n = 1002), or the nephrectomy, surgical removal of all or part of a kidney, group (n = 320). In the ablation group, 42 patients underwent radiofrequency ablation, while the remaining patients underwent cryoablation.

There was no evidence of a difference in the risk of cancer progression between patients who had ablation and the resection group. However, local recurrence of the disease was more frequent following ablation (2.41%) than resection (1.20%) and nephrectomy (0%).

According to investigators, distant metastasis occurred more frequently in patients who underwent nephrectomy (4.38%) than in those who underwent resection (1.90%) and ablation (1.67%). Investigators noted patients with ablation had the shortest hospital stays, and most returned home the same day. Additionally, the report of the fewest 30-day post-treatment hospital contacts, suggested a reduced instance of complications.

For additional insight into the new research, 

spoke to Iben Lyskjær, PhD, associate professor and leader of the Lyskjær Group at the Department of Molecular Medicine (MOMA) at Aarhus University.

 The data was prefaced by the fact that stage T1a renal cell carcinoma is often found incidentally during CT scans for other reasons. How has this led to a gap in care, and how can clinicians proactively manage this pressure on their health care systems?

Lyskjær: The widespread use of cross-sectional imaging has led to a marked increase in the incidence of small renal masses detected incidentally, particularly stage T1a tumors. Many of these lesions are asymptomatic and biologically indolent, but once detected, they enter a clinical pathway that often includes repeated imaging, multidisciplinary evaluation, and intervention.

This has created a structural pressure on healthcare systems: more patients are diagnosed, but not all necessarily require invasive treatment. The key challenge is distinguishing which tumors require active intervention from those that can be safely monitored.

Proactive management involves strengthening risk stratification strategies, incorporating active surveillance where appropriate, and ensuring access to minimally invasive treatment options such as ablation for selected patients. The goal is not simply to treat more, but to treat more appropriately.

HCPLive: When discussing the prospect of ablation with their patients compared to standard of care, what key factors and risk identifiers should clinicians consider?

Lyskjær: When discussing ablation compared to partial nephrectomy, clinicians should consider:

Tumor size (strictly ≤4 cm for T1a in most settings)

Patient preference after balanced counseling

Yet, shared decision-making remains central.

Local recurrence of the disease was more frequent following ablation than resection and nephrectomy. Can you explain this finding in the context of why ablation remains a beneficial option? Is there ever a point when it wouldn’t be?

It is true that local recurrence rates are generally higher after ablation compared to surgical resection. This is expected because surgery physically removes the entire tumor with a margin, whereas ablation relies on complete thermal destruction in situ.

However, several important nuances should be emphasized:

Local recurrences after ablation are often detected early through structured follow-up.

Cancer-specific survival for appropriately selected T1a tumors appears comparable in many studies.

Therefore, the slightly higher local recurrence rate must be interpreted in the context of lower procedural burden and shorter hospital stay. Ablation are not be appropriate for larger tumors, centrally located lesions, or in cases where imaging guidance cannot ensure adequate margins.

Are there any findings on whether radiofrequency ablation had any distinct outcomes from cryoablation? Is this an area of research you would consider meaningful?

Lyskjær: Our study primarily focused on cryoablation, with only few radiofrequency ablation procedures performed, and therefore we could not compare the difference in outcome of these. While radiofrequency ablation and cryoablation are both established thermal techniques, cryoablation offers certain technical advantages, including real-time visualization of the ice ball, which may allow more precise control of margins.

Further direct comparative research would be meaningful, particularly in standardized cohorts with long-term follow-up. However, operator experience and institutional expertise are likely just as important as the specific energy modality.

HCPLive: Looking ahead, how should clinicians implement these findings into their healthcare systems immediately to build a long-term strategy to improve patient outcomes?

Lyskjær: Clinicians should not interpret our findings as a call to replace surgery, but rather to refine patient selection.

Ensuring that ablation is considered in multidisciplinary tumor boards for appropriate T1a cases

Strengthening follow-up protocols after ablation

Integrating patient-specific factors (comorbidity, renal function, life expectancy) into decision-making as well as patient preference

Continued evaluation of functional outcomes

Clear national or international guidelines on patient selection

The overarching aim is individualized care — selecting the right treatment for the right patient — rather than promoting one modality universally.

Minimally invasive procedure effectively treats small kidney cancers. EurekAlert! Published March 3, 2026. Accessed March 3, 2026. 

https://www.eurekalert.org/news-releases/1117633

Articles

A 10-year Danish registry cohort of 1,862 adults with T1a RCC found ablation yielded cancer progression risk comparable to partial resection, while shortening length of stay and reducing early post-treatment hospital contacts. Local recurrence was modestly higher with ablation (2.41%) versus resection (1.20%) and nephrectomy (0%), yet recurrences are often detected early and amenable to repeat ablation. Distant metastases were most frequent after nephrectomy. Rising incidental detection of small renal masses intensifies demand for risk stratification, surveillance, and appropriate minimally invasive options.

Lyskjaer walks clinicians through 10-year data from a nationwide cohort study comparing ablation and surgery for renal cancer.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Ablation Offers Faster Recovery, Fewer Complications for Small Kidney Cancers

What Are the Invisible Burdens Carried By Physician Moms?

 podcast, Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale School of Medicine, sat down with Jennifer L. Hsiao, MD, a dermatologist and clinical associate professor of clinical dermatology at Keck Medicine of the University of Southern California, for a candid, clinician-focused discussion on the “invisible load” carried by physician mothers, and how it intersects with high-acuity 

The conversation moved beyond surface-level work-life balance tips and into the cognitive realities of dual roles: managing complex dermatologic disease while simultaneously running a household. Shahriari opened by naming what many clinician mothers experience but rarely articulate. In addition to diagnosing hidradenitis suppurativa (HS), adjusting biologics, managing portal messages, and keeping clinic flow on track, there is an ever-running mental checklist in the background; school forms, snack logistics, summer camp registration, call schedules, and family appointments.

She noted that physician mothers are often so high-functioning that their exhaustion is invisible to colleagues and patients alike. Hsiao reflected that while she is fully present when inside a patient room, listening intently, formulating management plans, and making therapeutic decisions, it is the transitional moments between patients where cognitive overload surfaces. She likened her brain to an internet browser with multiple open tabs: clinical trial responsibilities, patient care follow-ups, children’s schedules, seasonal planning, and routine medical and dental appointments.

The fragmentation is less about lack of focus and more about relentless context switching. Importantly for practicing clinicians, Hsiao highlighted the activation energy required to move between domains. Once the brain shifts from clinic mode to personal logistics, it can be difficult to recalibrate. Ironically, she noted that back-to-back patient visits sometimes feel easier because there is no opportunity for mental drift. The “lull” moments, when one checks email or text messages, can derail efficiency and compound stress.

The discussion also touched on sleep and anticipatory planning. Shahriari referenced data suggesting that women, particularly mothers, often engage in active next-day planning at bedtime—contrasting with male sleep patterns that may involve less cognitive processing. Both physicians described difficulty fully “shutting off,” frequently waking at night attuned to their children’s needs. The physiological hypervigilance, whether biologically driven or socially conditioned, contributes to chronic fatigue.

A central theme was the persistent sense of underperformance. Hsiao candidly shared that she often feels behind at work, with unanswered emails, administrative tasks, research obligations, while simultaneously describing occasionally not feeling present at home. The tension is particularly acute when children explicitly call attention to divided attention, such as asking a parent to put down a phone. For high-achieving physicians accustomed to excellence, perceived mediocrity in either domain can be psychologically distressing.

Shahriari emphasized that common advice to “be present” lacks actionable guidance. In response, she described implementing structured boundaries: dedicating a protected window from 5 to 7 pm exclusively to her child, limiting phone access to urgent contacts, and deferring noncritical communications. While not flawless, the structure provides psychological containment. However, Shahriari acknowledged the tradeoff: deferred work often encroaches on sleep, illustrating that balance frequently involves redistribution rather than elimination of strain.

For clinician audiences, the exchange underscores several key takeaways: cognitive load management is a professional competency issue; context switching carries efficiency costs; and intentional boundary-setting, though imperfect, may mitigate burnout. The conversation reframes physician-mother stress not as individual inadequacy but as a structural reality of modern medical practice.

Ultimately, Shahriari and Hsiao model transparent dialogue about the dual demands placed on physician mothers, an approach that may help normalize these experiences within academic and clinical dermatology.

Editor’s note: This summary was developed with the help of AI tools.

Videos

This segment of the February episode of The Medical Sisterhood podcast highlights burdens faced by those balancing motherhood with being a physician.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

February 2026 was defined by durability data and real-world insight across inflammatory bowel disease (IBD), with multiple long-term analyses presented at the 21st Congress of European Crohn’s and Colitis Congress (ECCO). Extended findings from the LUCENT clinical program reinforced sustained efficacy and safety of mirikizumab in ulcerative colitis (UC) through 4 years of continuous therapy, strengthening its position as a potential disease-modifying option. Complementing this, head-to-head SEQUENCE data continued to shape treatment sequencing decisions in Crohn’s disease, particularly for patients with prior anti-TNF exposure, while interim results from the real-world PROFUNDUS study helped clarify how upadacitinib performs outside the constraints of randomized trials.

February also highlighted the importance of long-term safety, durability, and accurate disease characterization. 3-year extension data from VIVID-2 offered additional reassurance regarding sustained benefit of IL-23p19 inhibition in Crohn’s disease. At the same time, efforts to refine ICD coding for short bowel syndrome underscored how classification and documentation influence the understanding of true disease burden, resource utilization, and care delivery.

Check out this February 2026 gastroenterology month in review for a recap of 

’s coverage of the top GI news and research from the past few weeks:

LUCENT: Durable UC Control With Mirikizumab Through 4 Years, With Fernando Magro, MD, PhD

Long-term findings from the LUCENT clinical program continue to strengthen the case for mirikizumab (Omvoh) as a potential disease-modifying therapy in moderately-to-severely active UC. Data presented at the 21st Congress of ECCO demonstrate the p19-directed interleukin (IL)-23 monoclonal antibody’s sustained efficacy and safety through 212 weeks of continuous treatment across the LUCENT-1 (induction), LUCENT-2 (maintenance), and LUCENT-3 (open-label extension) trials.

From Induction to Year 4: Mirikizumab’s Lasting Impact in Ulcerative Colitis

How Head-to-Head SEQUENCE Data Shape Crohn’s Disease Treatment Decisions, With Raja Atreya, MD

New long-term data from the SEQUENCE program, presented at the the 21st Congress of ECCO, continue to reinforce the clinical impact of risankizumab (Skyrizi) in moderate-to-severe Crohn’s disease, particularly among patients with prior anti-TNF failure. In discussing the findings, Raja Atreya, MD, head of the IBD Center at University Hospital of Erlangen, characterized SEQUENCE as a “landmark” trial and emphasized that its design and durability data are directly shaping real-world decision-making.

Sustained Remission in Hard-to-Treat Crohn’s: Insights From SEQUENCE

PROFUNDUS: Real-World Outcomes With Upadacitinib in Ulcerative Colitis, With Remo Panaccione, MD

New interim data from the ongoing PROFUNDUS study, presented at the 21st Congress of ECCO, provide important real-world insight into the effectiveness and safety of upadacitinib (Rinvoq) in patients with moderate-to-severe UC. While randomized controlled trials established the drug’s efficacy under tightly controlled conditions, the PROFUNDUS findings help clarify how those results translate into everyday clinical practice.

Real-World Upadacitinib Results in Ulcerative Colitis

3-Year Efficacy, Safety of Mirikizumab in Crohn’s Disease: Insights From VIVID-2, With Edward Barnes, MD, MPH

Long-term durability remains one of the central questions in the management of moderate-to-severe Crohn’s disease. While many advanced therapies demonstrate strong induction and shorter-term maintenance data, clinicians often grapple with whether those benefits persist and whether safety signals emerge with longer exposure.

New 3-year results from the ongoing VIVID-2 extension study offer important insight into the sustained efficacy and safety of mirikizumab, a selective IL-23p19 monoclonal antibody that earned US Food and Drug Administration approval for Crohn’s in January 2025 based on positive results from the phase 3 VIVID-1 study in adults with moderately to severely active Crohn’s who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, and/or biologics.

Long-Term Crohn’s Disease Management: Inside the VIVID-2 Mirikizumab Data

ICD-10 Adoption and the True Burden of Short Bowel Syndrome, With Alan Buchman, MD, MSPH

Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology. In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications. His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice.

Catch up on durability data and real-world insight from trials across inflammatory bowel disease and short bowel syndrome.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

5 Gastroenterology Headlines You Missed in February 2026

Long-Term PIONEER Data Reinforce Avapritinib’s Benefit–Risk Profile in ISM, with Cem Akin, MD

Avapritinib continues to deliver durable symptom control and quality-of-life improvements nearly 4 years into treatment for patients with indolent systemic mastocytosis (ISM), reinforcing its role as a long-term targeted therapy for this chronic disease.

Avapritinib was approved for treating ISM by the United States (US) Food and Drug Administration (FDA) in May 2023.

 Updated data from the Phase 2/3 PIONEER trial (NCT03731260) were presented at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, by Cem Akin, MD, Professor of Medicine at the University of Michigan Division of Allergy and Immunology. 

In the updated PIONEER analysis, 226 patients with indolent systemic mastocytosis initiated avapritinib 25 mg once daily across Parts 1, 2, and 3. The median duration of treatment was 46.5 months (range, 0.7–67.2 months).

Long-term efficacy was sustained through approximately 4 years. Among all patients treated with avapritinib, the mean change from baseline in ISM-SAF TSS was −17.66 (SD, 19.32) at Week 48 (n=141) and −17.66 (SD, 19.07) at Week 204 (approximately 4 years; n=85). For the most severe symptom domain (Figure 3), improvement was maintained at 1 year (n=193) and 4 years (n=85).

 at AAAAI, AKin emphasized the importance of the long-term consistency of benefit for ISM, where more than 80% of patients fall into the non-advanced category and historically have relied only on symptomatic therapies such as antihistamines. Prior to avapritinib, available treatments did not meaningfully reduce mast cell burden or target the underlying KIT D816V mutation, which drives over 90% of ISM cases.

Quality-of-life gains were similarly durable: the mean percentage change from baseline in MC-QoL was −30.96% (SD, 37.48) at 1 year and −35.41% (SD, 35.71) at 4 years. In patients who dose-escalated to 50 mg once daily in Part 3 (n=74), median time on 50 mg was 16.5 months (range, 0.2–33.6). These patients had higher baseline KIT D816V VAF and symptom burden; after 24 weeks on 50 mg, 42 of 48 evaluable patients (88%) achieved stable-to-improved ISM-SAF TSS, including 38 with improved TSS, and 42 of 46 (91%) had stable-to-improved MC-QoL, including 38 with improvement.

Safety remained consistent with prior reports. In Part 2, any adverse events occurred in 128 patients (91%) receiving avapritinib 25 mg plus best supportive care versus 66 (93%) with placebo plus best supportive care; grade ≥3 adverse events occurred in 30 (21%) and 15 (21%), respectively. Serious adverse events were reported in 7 (5%) and 8 (11%), and treatment-related adverse events (TRAEs) in 77 (55%) and 32 (45%). In the combined 25 mg cohort across Parts 1–3 (N=226), any adverse events occurred in 224 patients (99%), grade ≥3 events in 108 (48%), serious adverse events in 53 (23%), and serious TRAEs in 3 (1%). TRAEs leading to discontinuation occurred in 6 patients (3%). Among those escalating to 50 mg (n=74), any adverse events occurred in 64 (86%), grade ≥3 events in 13 (18%), serious adverse events in 10 (14%), and grade ≥3 TRAEs in 1 (1%), with no serious TRAEs reported and no treatment discontinuations due to adverse events at the 50 mg dose.

“In the 4 year trial now we are extending those observations, there are some patients who are on the drug for more than 5 years, but on average, 4 year follow up, and the efficacy was sustained at the same level, maybe slightly even improved at 4 years than at 6-month and 1-year time frames,” Akin said.

Akin’s disclosures include Blueprint Medicines, Cogent, Telios, GSK,  and Novartis.

Akin C, Tashi T, Elberink HO, et al. Avapritinib continues to demonstrate durable symptom control with a well-tolerated safety profile: Long-term outcomes from PIONEER. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #509

FDA Approves Avapritinib for the Treatment of Adult Patients with Indolent Systemic Mastocytosis. News release. ACCC. May 24, 2023. 

https://www.accc-cancer.org/view/fda-approves-ayvakit-(avapritinib)-for-the-treatment-of-adult-patients-with-indolent-systemic-mastocytosis-(ism)

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Deep Diving into the Pathogenesis of C3 Glomerulopathy, With Sayna Norouzi

 is increasingly understood not as a single disease entity but as a histopathologic pattern of kidney injury driven by dysregulation of the alternative pathway of the complement system.

Although rare, new insights into complement dysregulation are reshaping its diagnostic and therapeutic framework, according to this recently published review.

“So I think the rarity of the disease is something that affects both sides,” said Sayna Norouzi, MD, clinical nephrologist and associate professor of medicine at Loma Linda University Medical Center. “A lot of physicians might not be comfortable treating C3G because they've never seen a patient before, and they don't feel comfortable starting treatment for these patients.”

With an estimated incidence of 0.2–2 cases per million people annually, C3G remains ultrarare and diagnostically challenging. Patients commonly present with proteinuria, hematuria, and progressive kidney function decline—features that overlap with other glomerular diseases. As a result, accurate diagnosis increasingly depends on understanding the underlying complement-mediated mechanism driving injury.

The complement system can be activated through 3 pathways: classical, lectin, and alternative. The classical pathway is triggered by antigen–antibody complexes, while the lectin pathway is activated by carbohydrate patterns on microbial surfaces. The alternative pathway is distinct in its ability to activate spontaneously through continuous low-level hydrolysis of C3, a process known as “C3 tick-over,” which generates C3a and C3b fragments.

Once initiated, the alternative pathway undergoes amplification through an enzymatic loop in which C3b binds factor B and is cleaved by factor D, forming the alternative pathway C3 convertase. This complex drives further C3 cleavage, creating a powerful amplification system. Under normal physiologic conditions, regulatory proteins, including complement factor H, complement factor I, and membrane cofactor protein (CD46), control this process by inactivating C3b and limiting C3 convertase activity to prevent host tissue injury.

Both genetic and acquired abnormalities contribute to dysregulation of the alternative pathway. Genetic variants have been identified in approximately 25%–40% of patients and affect complement components such as C3 and factor B, as well as regulatory proteins including factor H, factor I, complement factor H-related protein 5, and membrane cofactor protein. Acquired drivers, including autoantibodies stabilizing C3 convertase, may further amplify complement activation.

The downstream effect is uncontrolled alternative pathway activity, excessive C3 convertase formation, and dominant C3 deposition within the glomeruli, which has been described as the defining histopathologic feature of C3G.

According to investigators, the kidney appears particularly vulnerable to this dysregulation. The glomerular basement membrane lacks membrane-bound complement regulators and relies heavily on circulating regulators such as factor H for protection.

When this regulation fails, persistent complement activation generates proinflammatory mediators, including C3a and C5a, promotes opsonization through C3b, and culminates in the formation of the terminal membrane attack complex (C5b-9), ultimately driving glomerular cell injury and progressive renal dysfunction.

As understanding of these mechanisms deepens, clinicians are increasingly able to connect histopathology with molecular drivers of disease. For Norouzi and others in the field, this evolving insight represents more than scientific progress; it may help reduce diagnostic uncertainty and increase clinician confidence in managing a condition that, while rare, carries significant morbidity.

Editor's Note: Norouzi reports relevant disclosures with Calliditas, Travere, Apellis, and others.

Mashayekhi M, Zuckerman JE, Barratt J, et al. C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies. Kidney Medicine. 2026;8(3):101258. doi:

https://doi.org/10.1016/j.xkme.2026.101258

Gashu Ayehu, Atari M, Hassanein M, Jhaveri KD. C3 Glomerulopathy. Nih.gov. Published November 5, 2024. 

https://www.ncbi.nlm.nih.gov/books/NBK609090/

Norouzi discusses a recent review where 11 clinicians described C3G pathology and diagnosis.  

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Twice-Yearly Depemokimab Reduces Rescue Use in Recurrent CRSwNP, With Josesph Han, MD

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Alpha-1 antitrypsin deficiency

6 Hepatology Headlines You Missed in February 2026

In this segment from the latest episode of the Skin of Color Savvy podcast, progress in skin health equity and advancements still needed in 2026 are highlighted.

Where Are We in 2026 in Skin Health Equity Progress?

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.

Video Series

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Wei-Xing Zong, PhD, is Distinguished Professor and Chair of the Department of Chemical Biology at Rutgers University.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management. 

Dietary Protein as a Modifiable Risk Factor in Liver Cancer, With Wei-Xing Zong, PhD

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Berotralstat Cuts HAE Attack Burden in APeX-P Interim Analysis, With Jolanta Bernatoniene, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up with FDA decisions, key trial results, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

5 Cardiology Headlines You Missed in February 2026

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

ADVANCE OUTCOMES: Ralinepag Outperforms Placebo in Slowing Disease Progression in PAH

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

Latest News

Ablation Offers Faster Recovery, Fewer Complications for Small Kidney Cancers

What Are the Invisible Burdens Carried By Physician Moms?

5 Gastroenterology Headlines You Missed in February 2026

Long-Term PIONEER Data Reinforce Avapritinib’s Benefit–Risk Profile in ISM, with Cem Akin, MD

Deep Diving into the Pathogenesis of C3 Glomerulopathy, With Sayna Norouzi